Venkat Pharma Peer Comparison

BSE: 532093

₹3.40

₹-0.17 (-4.76%)

As on 18-May-2015IST

Market cap

₹2 Cr

Revenue (TTM)

₹-- Cr

P/E Ratio

--

P/B Ratio

-0.7

Div. Yield

0 %

Edit

	Venkat Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	2	30,075	30,128	28,384	25,980
Revenue (₹ Cr)	--	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-0.03	414.00	288.22	-371.81	387.35
Net Margin (%)	--	11.23	14.79	-3.93	26.01
RoE (%)	--	8.38	29.77	-3.85	25.18
Price to Earnings	--	73.53	104.53	--	67.27
Price-To-Book	-0.66	5.97	22.44	3.55	15.06

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Venkat Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	--	5,609.42	37.09	--	55.51
Total Income	0.00	5,663.42	37.09	--	55.99
Total Expenditure	0.03	3,549.74	27.46	--	50.88
EBITDA	-0.03	2,059.68	9.63	--	4.63
Depreciation	0.02	122.14	3.08	--	0.90
EBIT	-0.04	1,937.54	6.55	--	3.73
Interest	0.00	215.37	2.58	--	1.11
Other Income	0.00	54.00	--	--	0.47
Exceptional Items	--	61.52	--	--	--
Profit before Tax	-0.04	1,837.69	3.97	--	3.09
Provision for Tax	--	258.21	1.13	--	1.04
Profit after Tax	-0.04	1,579.48	2.84	--	2.05

Liabilities (₹ Cr)

	Venkat Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	-2.54	2,704.18	40.33	--	8.16
Minority Interest	--	--	--	--	--
Non-Current Liabilities	19.07	1,520.80	7.33	--	1.19
Current Liabilities	1.33	1,773.48	21.75	--	16.97
Total Liabilities	18.00	6,022.66	69.41	--	26.51

Assets (₹ Cr)

	Venkat Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	0.85	2,671.53	49.55	--	5.37
Current Assets	17.02	3,326.93	19.86	--	20.95
Total Assets	18.00	6,022.66	69.41	--	26.51
Total Debt*	19.22	2,070.47	19.09	--	8.17
Net Current Assets	15.68	1,553.45	-1.89	--	3.98
Contingent Liabilities	10.39	79.85	0.70	--	--

Cashflow (₹ Cr)

	Venkat Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	0.00	1,532.40	3.99	--	--
Cash Flow from Investing Activities	0.01	1,085.37	-4.09	--	--
Cash from Financing Activities	--	-2,245.75	0.43	--	--
Net Cash Inflow / Outflow	0.00	372.02	0.33	--	0.00

Ratios

Profitability Ratios

	Venkat Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-0.26	42.17	11.29	--	29.13
ROE (%)	0.00	102.78	14.27	--	28.77
ROA (%)	-0.25	25.78	4.14	--	8.50
EBIT Margin (%)	--	37.68	25.96	--	9.19
Net Margin (%)	-1,304.68	27.89	7.66	--	3.67
Cash Profit Margin (%)	--	30.30	15.96	--	4.96

Growth Ratios

	Venkat Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	--	28.94	6.60	--	63.77
EBIT Growth (%)	-60.92	53.27	5.26	--	21.99
Net Profit Growth (%)	-21.39	427.46	12.54	--	52.02
EPS Growth (%)	-21.48	364.85	12.54	--	52.02
Book Value Growth (%)	-1.77	239.42	15.36	--	33.62

Valuation Ratios

	Venkat Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	12.71	0.00	--	0.00
Price / Book Value	-0.49	9.26	0.00	--	0.00
Dividend Yield (%)	0.00	0.25	--	--	--
EV/EBITDA	-726.97	11.00	4.10	--	1.79
Market Cap (₹ Cr)	--	21,979.56	0.00	--	0.00

Solvency Ratios

	Venkat Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	-7.57	0.77	0.47	--	1.00
Short term debt to equity ratio	-0.01	0.07	0.24	--	0.67
Current Ratio	12.77	1.88	0.91	--	1.23
Quick Ratio	11.25	1.28	0.85	--	0.87
Interest Coverage	-204.43	9.53	2.54	--	3.77

Operating Efficiency Ratios

	Venkat Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	--	17.09	27.75	--	19.50
Asset Turnover	0.00	0.92	0.54	--	2.47
Receivable days	--	55.81	123.43	--	58.39
Inventory Days	--	63.29	10.53	--	37.68
Payable days	--	122.70	--	--	93.41
Cash Conversion Cycle	--	-3.60	--	--	2.66

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly